Immune suppression via lymphocyte depletion

Immune suppression via lymphocyte depletion describes the reduction in functional lymphocytes (T cells, B cells, and/or others) as a means to suppress the immune system. This can occur as a therapeutic strategy (e.g., before organ transplantation, in autoimmune disease, or in lymphocyte-depleting cancer therapies) or as a result of viral infection (e.g., HIV, measles)[1][2][4][6][7]. Lymphocyte depletion is achieved with agents such as monoclonal antibodies (e.g., alemtuzumab, anti-CD3, antithymocyte globulin), cytotoxic drugs, or radiation[4][6]. While this strategy reduces the risk of immune-mediated pathologies (like transplant rejection or autoimmune disease), it increases susceptibility to infections and, in some cases, may provoke secondary autoimmunity driven by abnormal immune repopulation[4][6]. The approach exploits mechanisms such as apoptosis, ADCC, and other immune clearance pathways; but it is not itself a receptor, enzyme, or defined protein target. In summary, “immune suppression via lymphocyte depletion” is a therapeutic concept or immunological outcome, not a distinct molecule, gene, receptor, or target. Use of this as a “target” is incorrect for structured drug discovery or pharmacological mapping[4][6].

Other names

Lymphocyte depletionlymphodepletionimmune suppression by lymphocyte depletion

Induction of apoptosis, cytolysis, and immune cell depletion via antibodies or cytotoxic drugs